Omeros Corporation (OMER) Drops 7.02% on February 18

Equities Staff |

Omeros Corporation (OMER) was one of the Russell 2000's biggest losers for Thursday February 18 as the stock slid 7.02% to $10.59, a loss of $-0.8 per share. Starting at an opening price of $11.37 a share, the stock traded between $10.51 and $11.38 over the course of the trading day. Volume was 316,435 shares over 2,612 trades, against an average daily volume of 399,052 shares and a total float of 37.97 million.

The losses send Omeros Corporation down to a market cap of $402.1 million. In the last year, Omeros Corporation has traded between $30.23 and $8.90, and its 50-day SMA is currently $12.48 and 200-day SMA is $15.33.

Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.

Omeros Corporation is based out of Seattle, WA and has some 103 employees. Its CEO is Gregory A. Demopulos.

For a complete fundamental analysis analysis of Omeros Corporation, check out Equities.com’s Stock Valuation Analysis report for OMER. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and…

Private Markets

Mesa-Marshall 2 Well Project

MESA Resources ("MESA") is sponsoring the development of the two well direct drilling project -- "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development of…

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.